Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit

June 04, 2025
REGENERON PHARMACEUTICALS, INC. (REGN) has successfully reached the price target forecast set by QuantWave, resulting in a profit of 27.18%. The forecast signal date was March 14, 2025, with a price of $665.89 and a predicted direction of short. On June 4, 2025, REGN reached the target price of $484.93. This achievement highlights the accuracy and effectiveness of QuantWave's analytics in predicting stock movements.

Market analysis shows that REGN experienced a gradual decline in price leading up to the target date, with various factors contributing to this downward movement. The pharmaceutical industry faced challenges such as regulatory changes, competition, and market volatility during this period, impacting REGN's stock performance. QuantWave's forecast took into account these market conditions and provided users with valuable insights to make informed investment decisions.

QuantWave offers users access to forecasts for a wide range of stocks, presenting opportunities for potential profits through its automated platform. For investors seeking to enhance their understanding of QuantWave's forecasting system, QuantSchool offers educational resources on professional investment strategies. QuantSchool delves into the key principles for generating consistent income using QuantWave's analytics, empowering users to make smarter investment choices.

Overall, the successful prediction of REGN's price target by QuantWave demonstrates the platform's reliability in forecasting stock movements and maximizing returns for investors.
If you want to leave a comment, then you need Login or Register





Other data for REGN

Related data

REGNJuly 5, 2025Regeneron Pharmaceuticals: Revolutionizing Healthcare with Innovative Drug Approvals  ~1 min.

Regeneron Pharmaceuticals, Inc. recently made headlines with the approval of Dupixent by the US FDA, in collaboration with Sanofi....

REGNJune 27, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors as UBS Lowers Price Target  ~1 min.

Regeneron Pharmaceuticals Inc. has been making waves in the biotech industry, with impressive financial and operating results....

REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 26.25%  ~1 min.

REGENERON PHARMACEUTICALS, INC. stock recently achieved the price target forecast set by QuantWave on March 21, 2025. The forecast indicated a short direction, with the stock price at $657....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit  ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target Forecast, Bringing 27.31% Profit  ~1 min.

On March 4, 2025, QuantWave, the automated forecasting platform, issued a short signal for REGENERON PHARMACEUTICALS, INC. stock when it was trading at $674.49....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits 29.73% Profit Target as Forecasted by QuantWave  ~1 min.

REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) achieved a significant milestone as it hit the price target forecasted by QuantWave, providing investors with a profit of 29.73%....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Short Forecast Target with 17.43% Profit  ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on July 1, 2022, predicted a short direction with a price of $593.76....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 21.51% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecast set by QuantWave, resulting in a profitable outcome for investors....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Forecast Target with a Profit of 30.6%  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecasted by QuantWave, resulting in a profit of 30.6% for investors who followed the short signal....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 34.08% Profit: A Success Story for QuantWave  ~1 min.

REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) recently achieved a price target forecast set by QuantWave, resulting in a remarkable profit of 34.08% for investors....

REGNApril 4, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits QuantWave's Price Target Forecast with a Profit of 17.34%  ~1 min.

On January 23, 2025, QuantWave, the automated forecasting platform, issued a short forecast signal for REGENERON PHARMACEUTICALS, INC. stock when it was trading at 692.73 $....

REGNMay 9, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 25.34% Profit Margin: A Victory for QuantWave  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecasted by QuantWave, resulting in a profit margin of 25.34%....

REGNAugust 13, 2024REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 14.62%  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully achieved the price target forecast as predicted by QuantWave's automated forecasting platform....

REGNApril 8, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target with 20% Profit: QuantWave Analysis  ~1 min.

In a recent success for QuantWave's forecasting platform, the stock of REGENERON PHARMACEUTICALS, INC. has hit its price target with a 20% profit margin....

REGNJanuary 24, 2025Regeneron Pharmaceuticals, Inc. Announces Positive Results from Clinical Trial of its Breakthrough Drug  ~1 min.

Regeneron Pharmaceuticals, Inc., a leading biotechnology company, has recently announced positive results from a clinical trial of its groundbreaking drug....